硫嘌呤治疗的炎症性肠病患者结节性再生性增生临床病程
Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-06-01
结节性再生性增生(NRH)是一种认识不足的肝脏病变,在硫嘌呤治疗的炎症性肠病(IBD)患者中日益被识别。本研究旨在识别接受硫唑嘌呤、巯嘌呤和/或硫鸟嘌呤治疗的IBD患者中的NRH病例,并描述其临床病程。
要点
- NRH在硫嘌呤治疗的IBD患者中日益被识别。
- NRH表现高度可变,从无症状到非肝硬化性门脉高压症状。
- NRH预后未知,难以建立最佳管理策略。
核心结论
- NRH是一种认识不足的肝脏病变,在硫嘌呤治疗的IBD患者中日益被识别,其表现高度可变且预后未知。
研究设计与样本
- 本研究旨在识别接受硫唑嘌呤、巯嘌呤和/或硫鸟嘌呤治疗的IBD患者中的NRH病例,并描述其临床病程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD).1 It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and the prognosis is unknown.2 The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course.
来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。
引用
- Simsek M, Meijer B, Ramsoekh D, et al. Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. Clin Gastroenterol Hepatol. 2018. PMID: 29775790. doi:10.1016/j.cgh.2018.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。